A Bowman-Birk type chymotrypsin inhibitor peptide from the amphibian, Hylarana erythraea

Luyao Zhang, Xiaoling Chen, Yue Wu, Mei Zhou, Chengbang Ma, Xinping Xi, Tianbao Chen, Brian Walker, Christopher Shaw, Lei Wang

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)
238 Downloads (Pure)


The first amphibian skin secretion-derived Bowman-Birk type chymotrypsin inhibitor is described here from the Asian green frog, Hylarana erythraea, and was identified by use of molecular cloning and tandem mass spectrometric amino acid sequencing. It was named Hylarana erythraea chymotrypsin inhibitor (HECI) and in addition to inhibition of chymotrypsin (Ki = 3.92 ± 0.35 μM), the peptide also inhibited the 20 S proteasome (Ki = 8.55 ± 1.84  μM). Additionally, an analogue of HECI, named K9-HECI, in which Phe9 was substituted by Lys9 at the P1 position, was functional as a trypsin inhibitor. Both peptides exhibited anti-proliferation activity against the human cancer cell lines, H157, PC-3 and MCF-7, up to a concentration of 1 mM and possessed a low degree of cytotoxicity on normal cells, HMEC-1. However, HECI exhibited higher anti-proliferative potency against H157. The results indicate that HECI, inhibiting chymotryptic-like activity of proteasome, could provide new insights in treatment of lung cancer.
Original languageEnglish
Article number 5851
Number of pages9
JournalScientific Reports
Publication statusPublished - 11 Apr 2018


Dive into the research topics of 'A Bowman-Birk type chymotrypsin inhibitor peptide from the amphibian, Hylarana erythraea'. Together they form a unique fingerprint.

Cite this